Jeonghee Cho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9299036/publications.pdf

Version: 2024-02-01

30	4,875	361045	454577
papers	citations	20 h-index	30 g-index

30	30	30	9273
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell, 2012, 150, 1107-1120.	13.5	1,591
2	Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007, 450, 893-898.	13.7	1,020
3	Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	7.7	455
4	Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. PLoS ONE, 2011, 6, e20351.	1.1	338
5	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14476-14481.	3.3	246
6	Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO Journal, 2002, 21, 4831-4840.	3.5	245
7	Tpl2/Cot Signals Activate ERK, JNK, and NF-ÎºB in a Cell-type and Stimulus-specific Manner. Journal of Biological Chemistry, 2005, 280, 23748-23757.	1.6	127
8	Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer, 2013, 119, 1627-1635.	2.0	108
9	Cetuximab Response of Lung Cancerâ€“Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization. Cancer Research, 2013, 73, 6770-6779.	0.4	87
10	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biology and Therapy, 2009, 8, 2042-2050.	1.5	78
11	Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nature Structural and Molecular Biology, 2015, 22, 703-711.	3.6	72
12	Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies. Cancer Research, 2011, 71, 7587-7596.	0.4	70
13	Phosphorylation at Thr-290 regulates Tpl2 binding to NF-ÂB1/p105 and Tpl2 activation and degradation by lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2350-2355.	3.3	64
14	Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes and Development, 2013, 27, 197-210.	2.7	61
15	Tpl2 (Tumor Progression Locus 2) Phosphorylation at Thr290 Is Induced by Lipopolysaccharide via an Iº-B Kinase-Î²-dependent Pathway and Is Required for Tpl2 Activation by External Signals. Journal of Biological Chemistry, 2005, 280, 20442-20448.	1.6	50
16	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification. Molecular Cancer Therapeutics, 2014, 13, 2527-2536.	1.9	34
17	Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals, 2021, 14, 589.	1.7	32
18	Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors. Oncotarget, 2016, 7, 6538-6551.	0.8	29

#	Article	IF	Citations
19	Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. Cancers, 2021, 13, 1205.	1.7	25
20	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer, 2014, 13, 141.	7.9	24
21	MerTK is a novel therapeutic target in gastric cancer. Oncotarget, 2017, 8, 96656-96667.	0.8	23
22	Colorectal adenocarcinomaâ€derived EGFR mutants are oncogenic and sensitive to EGFRâ€targeted monoclonal antibodies, cetuximab and panitumumab. International Journal of Cancer, 2020, 146, 2194-2200.	2.3	20
23	Exome and transcriptome sequencing identifies loss of PDLIM2 in metastatic colorectal cancers. Cancer Management and Research, 2017, Volume 9, 581-589.	0.9	19
24	Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. Cells, 2019, 8, 878.	1.8	17
25	Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants. Oncotarget, 2015, 6, 8839-8850.	0.8	12
26	Autophosphorylation of the carboxylâ€terminal domain is not required for oncogenic transformation by lungâ€cancer derived <scp>EGFR</scp> mutants. International Journal of Cancer, 2018, 143, 679-685.	2.3	8
27	Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. Oncotarget, 2016, 7, 13797-13809.	0.8	7
28	Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective. BMB Reports, 2020, 53, 133-141.	1.1	6
29	Analogues of Dehydroacetic Acid as Selective and Potent Agonists of an Ectopic Odorant Receptor through a Combination of Hydrophilic and Hydrophobic Interactions. ChemMedChem, 2017, 12, 477-482.	1.6	4
30	Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells. Biochemical and Biophysical Research Communications, 2018, 503, 710-714.	1.0	3